GLP-1R agonists and uses thereof
The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
1. A compound or a pharmaceutically acceptable salt thereof; wherein the compound is represented by the following structure:
2. A compound or a pharmaceutically acceptable salt thereof; wherein the compound is represented by the following structure:
3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, and a compound represented by the following structure:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, and a compound represented by the following structure:
or a pharmaceutically acceptable salt thereof.